Intravenous iron therapy in heart failure with preserved ejection fraction: how far have we walked?

Graphical AbstractTreatment effects on exercise capacity and quality of life in contemporary intravenous iron therapy or heart failure with preserved ejection fraction (HFpEF) trials Estimated differences in changes from baseline to follow-up in 6-min walk test distance (6MWTD) and the Kansas City Cardiomyopathy Questionnaire (KCCQ) scores between patients receiving treatment vs. placebo from recent randomized controlled trials evaluating intravenous iron therapy or other treatments in HFpEF. The top bars of each assessment represent baseline values and the lower bars represent the estimated differences in changes from baseline. Only the trials that report both values are presented. The HEART-FID study does not report KCCQ scores.13 Patient characteristics and baseline values reflect those of the treatment group. Assessments of 6MWTD and KCCQ scores were conducted at various time points as specified. FCM, ferric carboxymaltose; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; NA, not availableOpen in new tabDownload slide